Recomendações sobre diagnóstico e tratamento da esclerose sistêmica

Sampaio-Barros, Percival Degrava; Zimmermann, Adriana Fontes; Müller, Carolina de Souza; Borges, Cláudia Tereza Lobato; Freire, Eutília Andrade Medeiros; Maretti, Giselle Baptista; Marques Neto, João Francisco; Salgado, Maria Cecília Fonseca; Sauma, Maria de Fátima Lobato da Cunha; Azevedo, Mário Newton Leitão de; Fontenelle, Sheila; Kayser, Cristiane.
Rev. bras. reumatol ; 53(3): 258-275, maio-jun. 2013.
Artículo en Portugués | LILACS | ID: lil-686088

Documentos relacionados

  1. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects.
  2. [How do I treat interstitial lung disease in systemic sclerosis?]
  3. OnabotulinumtoxinA for Systemic Sclerosis-associated Raynaud's Phenomenon: A Multi-Institutional Study on Accessibility and Effectiveness.
  4. A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud's.
  5. Novel Use of Bosentan for Postoperative Wound Healing of the Foot in Systemic Sclerosis.
  6. The Collaborative National Quality and Efficacy Registry for Scleroderma: association of medication use on gastrointestinal tract symptoms in early disease and the importance of tobacco cessation.
  7. Treatment of systemic sclerosis-associated digital ulcers: recommendations of the Turkish Society for Rheumatology.
  8. Effects of Bosentan in the Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: A Longitudinal, Multicenter, Uncontrolled Trial.
  9. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis].
  10. Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus Meetings.